Wuhan Jiulong Renfu Pharmaceutical Co., Ltd.

The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation drospirenone ethinylestradiol tablets (II) (specifications: drospirenone 3 mg and ethinylestradiol 0.02 mg; produced by Wuhan Jiulong Renfu Pharmaceutical Co., Ltd.) and the reference preparation drospirenone ethinylestradiol tablets (II) (specifications: drospirenone 3 mg and ethinylestradiol 0.02 mg; produced by Bayer Weimar GmbH & Co. KG) in healthy adult female participants after a single oral administration in the fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fed state. Secondary purpose of the study is to study the safety of the test preparation drospirenone ethinylestradiol tablets (II) (specifications: drospirenone 3 mg and ethinylestradiol 0.02 mg) and the reference preparation drospirenone ethinylestradiol tablets (specifications: drospirenone 3 mg and ethinylestradiol 0.02 mg) in healthy adult female participants.

The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation drospirenone ethinylestradiol tablets (II) (specifications: drospirenone 3 mg and ethinylestradiol 0.02 mg; produced by Wuhan Jiulong Renfu Pharmaceutical Co., Ltd.) and the reference preparation drospirenone ethinylestradiol tablets (II) (specifications: drospirenone 3 mg and ethinylestradiol 0.02 mg; produced by Bayer Weimar GmbH & Co. KG) in healthy adult female participants after a single oral administration under fasting conditions, and to evaluate the bioequivalence of the two preparations when taken orally under fasting conditions. The secondary purpose of the study is to study the safety of the test preparation drospirenone ethinylestradiol tablets (II) (specifications: drospirenone 3 mg and ethinylestradiol 0.02 mg) and the reference preparation drospirenone ethinylestradiol tablets (specifications: drospirenone 3 mg and ethinylestradiol 0.02 mg) in healthy adult female participants.

Main purpose: To compare the absorption rate and extent of methylprednisolone tablets produced by Wuhan Jiulong Renfu Pharmaceutical Co., Ltd. with methylprednisolone tablets (trade name: Medrol®, reference preparation) produced by Pfizer Italia Srl in healthy human bodies according to the relevant provisions of bioequivalence test, and to investigate the bioequivalence of the two preparations in humans. Secondary purpose: To observe the safety of the test preparation methylprednisolone tablets and the reference preparation methylprednisolone tablets (Metrol®) in healthy subjects.